<DOC>
	<DOCNO>NCT02915796</DOCNO>
	<brief_summary>The main aim present study evaluate therapeutic potential safety transarterial infusion granulocyte colony stimulate factor ( G-CSF ) mobilize cluster differentiation ( CD ) 133 ( + ) cell combine percutaneous transluminal angioplasty ( PTA ) treatment knee ( BTK ) peripheral arterial disease ( PAD ) diabetic patient .</brief_summary>
	<brief_title>Autologous CD133 ( + ) Cells Adjuvant Below Knee Percutaneous Transluminal Angioplasty</brief_title>
	<detailed_description>CD133+ cell , bone marrow derive subpopulation adult hematopoietic progenitor cell , confers high proliferative , vasculogenic regenerative capacity vitro vivo . thereby suggest CD133+ cell may induce vasculogenesis , improve limb perfusion , prevent tissue loss restore ambulatory function patient critical limb ischemia . Although several small , randomized trial conduct far demonstrate safety autologous cell bone marrow origin treatment , report benefit find variable . A meta-analysis autologous bone marrow derive cell therapy critical limb ischemia trial suggest application autologous stem cell transplantation cure limb ischemic patient obviously effectiveness improvement ankle brachial pressure ( ABI ) limb ischemic patient . But dramatically reduce rate amputation . Therefore , present study , investigator aim evaluate therapeutic potential safety transarterial infusion g-csf-mobilized CD 133 ( + ) cell combine PTA treatment knee PAD diabetic patient .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Age range : 1875 year , Gender : Both 2 . Patients knee limb ischemia diabetes . 3 . Rutherford class 26 . 4 . Target lesion diameter reduction least 50 % occlusion longer 4 cm angiography . 5 . Have previous history stem cell therapy [ infusion CD133 endothelial progenitor cell ( EPC ) ] . Written inform consent sign patient representative . 1 . Previous bypass surgery stent placement ipsilateral low limb 2 . History intolerance antiplatelet therapy , heparin , contrast medium . 3 . Presence follow condition : 1. severe liver disease ( ascites , esophageal varix , liver transplantation ) ; 2. hemodynamic instability ; 3 . Severely impaired renal function ( serum creatinine level &gt; 2.5 mg/dL ) . 4 . Receiving immunosuppressive therapy ; 5 . History decompensated heart failure ( New York Heart Association class III IV level ) myocardial infarction , heart bypass surgery ; 6 . Bleeding diathesis ; 7 . Active systemic bacterial infection ; 8 . Acute thrombophlebitis deep vein thrombosis target limb ; 4 ) Pregnant lactate woman , woman child bear age unable unwilling use effective contraception study period ; 5 ) Expected survival time le 24 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Endothelial progenitor cell</keyword>
	<keyword>Percutaneous transluminal angioplasty</keyword>
</DOC>